Surrozen, Inc 8-K, filed Oct 17, 2025
Surrozen, Inc. (SRZN)
About this 8-K
Surrozen, Inc filed this 8-K on October 17, 2025, reporting on events of October 14, 2025.
Items reported
- Item 1.02: Ended a material agreement
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: +1 |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
|||
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.02 Termination of a Material Definitive Agreement.
On October 14, 2025, Surrozen, Inc. (the “Company”) received notice from TCGFB, Inc. (“TCGFB”) that TCGFB has elected to terminate the Collaboration Agreement (the “Collaboration Agreement”) between TCGFB and the Company, dated October 31, 2024. TCGFB exercised its right to terminate the Collaboration Agreement for convenience and neither TCGFB nor the Company will incur any termination penalties. The termination will be effective as of November 13, 2025.
Under the terms of the Collaboration Agreement, the Company provided antibody discovery services. TCGFB owned all TGF-β product related intellectual property. In exchange for the Company’s research services, TCGFB agreed to pay the Company up to $6.0 million in the aggregate, plus any third-party costs, and issued the Company a warrant exercisable for up to 3.4 million shares of TCGFB common stock at an exercise price of $0.0001 per share based on certain vesting conditions. TCGFB was founded by The Column Group and the Collaboration Agreement constituted a related party transaction because entities affiliated with The Column Group hold more than 5% of the Company’s common stock and Dr. Kutzkey, a member of the Company’s board of directors, serves as Managing Partner of The Column Group.
The foregoing summary of the terms of the Collaboration Agreement is qualified in its entirety by reference to the Collaboration Agreement, which was filed as Exhibit 10.28 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
SURROZEN, INC. |
|
|
|
|
Date: |
October 17, 2025 |
By: |
/s/ Charles Williams |
|
|
|
Name: Charles Williams |